riluzole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2382 1744-22-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • riluzole
  • rilutek
  • rilutor
  • 6-Trifluoromethoxybenzothiazol-2-ylamine
  • riluzole hydrochloride
  • riluzole HCl
  • RP54274
  • RP-54274
The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective. The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. Riluzole has also been shown, in a single study, to delay median time to death in a transgenic mouse model of ALS. These mice express human superoxide dismutase bearing one of the mutations found in one of the familial forms of human ALS. It is also neuroprotective in various in vivo experimental models of neuronal injury involving excitotoxic mechanisms. In in vitro tests, riluzole protected cultured rat motor neurons from the excitotoxic effects of glutamic acid and prevented the death of cortical neurons induced by anoxia. Due to its blockade of glutamatergic neurotransmission, riluzole also exhibits myorelaxant, sedative, and anticonvulsant properties.
  • Molecular weight: 234.20
  • Formula: C8H5F3N2OS
  • CLOGP: 3.23
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 48.14
  • ALOGS: -3.77
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 64 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 1995 FDA COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyotrophic lateral sclerosis 96.85 43.91 16 748 1147 63487111
Death 94.02 43.91 57 707 374324 63113934

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyotrophic lateral sclerosis 85.62 33.57 16 952 1002 34954961
Death 70.37 33.57 69 899 397980 34557983
Portal vein thrombosis 54.72 33.57 14 954 3774 34952189
Pancreatitis acute 42.64 33.57 19 949 28122 34927841
Pancreatitis relapsing 36.99 33.57 7 961 467 34955496

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyotrophic lateral sclerosis 125.79 29.52 23 1558 1792 79741015
Death 64.89 29.52 67 1514 566447 79176360
Portal vein thrombosis 53.34 29.52 14 1567 5813 79736994
Interstitial lung disease 47.82 29.52 29 1552 112571 79630236
Pancreatitis acute 47.49 29.52 22 1559 49582 79693225
Gastrostomy 44.52 29.52 9 1572 1184 79741623
Disease progression 43.54 29.52 33 1548 184329 79558478
Inappropriate antidiuretic hormone secretion 39.37 29.52 16 1565 26297 79716510
Pancreatitis relapsing 34.13 29.52 7 1574 989 79741818
Respiratory failure 33.32 29.52 28 1553 180883 79561924
Dysphoria 32.19 29.52 9 1572 4725 79738082
Depersonalisation/derealisation disorder 29.77 29.52 7 1574 1855 79740952

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07XX02 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA CS M0483511 Benzothiazoles
FDA EPC N0000175740 Benzothiazole
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Amyotrophic lateral sclerosis indication 86044005 DOID:332
Alcoholism contraindication 7200002
Hyperbilirubinemia contraindication 14783006 DOID:2741
Jaundice contraindication 18165001
Interstitial pneumonia contraindication 64667001
Liver function tests abnormal contraindication 166603001
Drug-induced hepatitis contraindication 235876009
Neutropenic disorder contraindication 303011007 DOID:1227
Fever greater than 100.4 Fahrenheit contraindication 426000000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.47 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
50MG/10ML TIGLUTIK KIT ITALFARMACO SA N209080 Sept. 5, 2018 RX SUSPENSION ORAL 8765150 March 12, 2029 A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel BLOCKER IC50 4.30 IUPHAR
Sodium-dependent noradrenaline transporter Transporter Ki 5.77 DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel ACTIVATOR IC50 5.70 IUPHAR
Glutamate receptor ionotropic, NMDA 3A Ion channel WOMBAT-PK
Small conductance calcium-activated potassium channel protein 3 Ion channel ACTIVATOR EC50 4.90 IUPHAR
Small conductance calcium-activated potassium channel protein 1 Ion channel ACTIVATOR EC50 4.68 IUPHAR
Short transient receptor potential channel 5 Ion channel ACTIVATOR EC50 5.04 IUPHAR
Pteridine reductase 1 Enzyme Ki 5.40 CHEMBL
Small conductance calcium-activated potassium channel protein 2 Ion channel ACTIVATOR EC50 4.89 IUPHAR

External reference:

IDSource
4020941 VUID
N0000148421 NUI
D00775 KEGG_DRUG
4020941 VANDF
C0073379 UMLSCUI
CHEBI:8863 CHEBI
657 PDB_CHEM_ID
CHEMBL744 ChEMBL_ID
DB00740 DRUGBANK_ID
D019782 MESH_DESCRIPTOR_UI
5070 PUBCHEM_CID
2326 IUPHAR_LIGAND_ID
5912 INN_ID
7LJ087RS6F UNII
196501 RXNORM
162294 MMSL
5067 MMSL
5425 MMSL
d03869 MMSL
005183 NDDF
109141001 SNOMEDCT_US
386980005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Riluzole HUMAN PRESCRIPTION DRUG LABEL 1 0378-4145 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
EXSERVAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-350 FILM 50 mg ORAL NDA 29 sections
Riluzole HUMAN PRESCRIPTION DRUG LABEL 1 42291-775 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Riluzole Human Prescription Drug Label 1 62756-538 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Riluzole Human Prescription Drug Label 1 64980-191 TABLET, FILM COATED 50 mg ORAL NDA AUTHORIZED GENERIC 17 sections
Riluzole Human Prescription Drug Label 1 67877-286 TABLET 50 mg ORAL ANDA 26 sections
Riluzole Human Prescription Drug Label 1 67877-286 TABLET 50 mg ORAL ANDA 26 sections
riluzole HUMAN PRESCRIPTION DRUG LABEL 1 68462-381 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Riluzole HUMAN PRESCRIPTION DRUG LABEL 1 69076-200 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
Riluzole HUMAN PRESCRIPTION DRUG LABEL 1 69076-200 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
Riluzole HUMAN PRESCRIPTION DRUG LABEL 1 69076-200 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
Exservan HUMAN PRESCRIPTION DRUG LABEL 1 70510-2201 FILM 50 mg ORAL NDA 30 sections
Exservan HUMAN PRESCRIPTION DRUG LABEL 1 70510-2201 FILM 50 mg ORAL NDA 30 sections
Exservan HUMAN PRESCRIPTION DRUG LABEL 1 70510-2201 FILM 50 mg ORAL NDA 30 sections
Rilutek HUMAN PRESCRIPTION DRUG LABEL 1 70515-700 TABLET 50 mg ORAL NDA 27 sections
Rilutek HUMAN PRESCRIPTION DRUG LABEL 1 70515-700 TABLET 50 mg ORAL NDA 27 sections
TIGLUTIK HUMAN PRESCRIPTION DRUG LABEL 1 70726-0303 LIQUID 50 mg ORAL NDA 31 sections
TIGLUTIK HUMAN PRESCRIPTION DRUG LABEL 1 70726-0303 LIQUID 50 mg ORAL NDA 31 sections